Foamix (FOMX) Tops Q1 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/28/2026
- S&P 500, Nasdaq set for higher open as SK Hynix lifts chips; Fed in focus
- SK Hynix shares surge after Q3 profit beats expectations
- Oil up over 1% as Saudi Arabian refinery attack reignites supply risk concerns
- Wendy's shares surge 16% on $1.4 billion takeover bid by Nelson Peltz’s Trian Fund
- UBS's new Brent price forecasts as Middle East supply risk supports oil prices
Foamix Reports First Quarter 2019 Financial Results and Provides Corporate Update
May 7, 2019 4:23 PM EDTFDA Accepts NDA for FMX101, Sets October 20, 2019 as PDUFA Action Date
Conference Call Scheduled for Wednesday May 8th at 8:30am Eastern Time
REHOVOT, Israel and BRIDGEWATER, N.J., May 07, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX) (Foamix Pharmaceuticals or the Company), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical therapies to address unmet needs in dermatology, today announced financial results for the first quarter ended March 31, 2019 and provided a corporate update.
Foamix has achieved a number of important... More



